MGD care paradigm shifts with new treatment devices

Article

Investigators review changes in ocular anterior segment blood flow and temperature after treatment of patients with meibomian gland dysfunction.

Reviewed by Takashi Itokawa, PhD, and Yuichi Hori, MD

The standard treatment for meibomian gland dysfunction (MGD) is application of warm compresses to the eye, with the goal of increasing the blood flow and temperature.

Care with a treatment device (LipiFlow, Johnson + Johnson) was found to be superior to warm compresses by increasing the palpebral and bulbar conjunctival temperature and blood flow compared with warm compresses, according to Takahashi Itokawa, PhD, from the Department of Ophthalmology, and Yuichi Hori, MD, professor and chair, Department of Ophthalmology, Toho University Omori Medical Center, Toho University School of Medicine, Tokyo, Japan.

The device applies localized head and pressure to the meibomian glands that results in evacuation of the meibum in the glands.

In their study, Itokawa, the first study author, and colleagues enrolled 13 eyes of 13 patients (mean age, 64.9 years) with MGD. The investigators measured the noninvasive tear break-up time (NIBUT) and the blood flow in the upper and lower eyelid skin and palpebral and bulbar conjunctiva. The measurements were performed before testing and then 5 minutes and 1 month after testing.

Itokawa reported that with application of the treatment device, the tear film stability improved until 1 month after treatment. Immediately after treatment, the temperature and the blood flow increased at 5 minutes after application of the treatment device. However, at 1 month, both parameters at all locations returned to normal, except for the blood flow in the bulbar conjunctiva.

When the treatment device results were compared with those achieved with warm compresses, the investigators reported that the temperature before and 5 minutes after use of the device were higher in all ocular locations compared with the temperatures obtained with warm compresses.

The changes in the blood flow prior to and 5 minutes after application of the treatment device in the palpebral and bulbar conjunctiva were also significantly higher than the blood flow obtained with warm compresses. However, the upper and lower eyelid skin did not become significantly warmer.

The investigators noted that conventional warm compresses heat the skin from the outside of the eyelid.

“However, LipiFlow heats the tissues from the inner side of the eyelids, by compression of the eyelid,” investigators said. “The difference in the palpebral temperature between before and after application of LipiFlow was twice that of the temperature achieved with warm compresses. LipiFlow adjusted the ocular surface more in patients with MGD for whom a higher temperature is needed to melt the meibum than in normal eyes.”

Takahashi Itokawa, PhD

Takashi.itokawa@med.toho-u.ac.jp

This article is adapted from Itokawa’s presentation at the Association for Research in Vision and Ophthalmology 2021 virtual annual meeting. He has no financial interest in this subject matter.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.